Literature DB >> 21813900

Treatment of patients with chronic obstructive pulmonary disease as practised in a defined Hong Kong community: a cross-sectional pilot survey.

W C Yu1, E Lb Tai, S N Fu, K C Kwong, Y C Yeung, Y Chang, Y K Yiu, C M Tam.   

Abstract

OBJECTIVES: To examine the characteristics of chronic obstructive pulmonary disease patients of the Kwai-Tsing area, Hong Kong, and the chronic treatments they received. DESIGN. Cross-sectional survey.
SETTING: Four clinic settings in Hong Kong: Respiratory Specialist Clinic, Princess Margaret Hospital (group 1); Medical Specialist Clinics, Princess Margaret Hospital (group 2); General Outpatient Clinics, Princess Margaret Hospital (group 3); South Kwai Chung Chest Clinic, Department of Health (group 4). PATIENTS: Thirty physician-diagnosed chronic obstructive pulmonary disease patients in each of the above groups with post-bronchodilator 1-second forced expiratory volume/forced vital capacity ratios of less than 70% predicted values, who had been followed up at any of the participating clinics for at least 6 months.
RESULTS: There were 111 male and nine female patients. The median age was 72.5 years and 79% had at least one medical co-morbidity. The mean duration of their chronic obstructive pulmonary disease was 9.8 years, and their mean post-bronchodilator 1-second forced expiratory volumes were 45% (for males) and 58% (for females) of predicted values. There were significantly fewer stage I and more stage IV patients in group 1. Influenza vaccination coverage within the previous 1 year was 54% and did not differ significantly between groups. Chronic obstructive pulmonary disease education was given significantly more often to group 1 patients. Short-acting beta agonists were used to treat all patients but long-acting bronchodilators and pulmonary rehabilitation were used almost exclusively in group 1. Overall, long-acting bronchodilators and pulmonary rehabilitation were offered to 16% and 5%, respectively, of those for whom these were indicated (according to international guidelines).
CONCLUSION: In general there was insufficient education and under-treatment for chronic obstructive pulmonary disease patients. Management of such patients warrants improvements by way of increased accessibility to structured education programmes, pulmonary rehabilitation programmes, long-acting bronchodilator drugs, and respiratory specialist care.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813900

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  5 in total

1.  Spirometry is underused in the diagnosis and monitoring of patients with chronic obstructive pulmonary disease (COPD).

Authors:  Wai Cho Yu; Sau Nga Fu; Emily Lai-Bun Tai; Yiu Cheong Yeung; Kwok Chu Kwong; Yui Chang; Cheuk Ming Tam; Yuk Kwan Yiu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-08-26

2.  Factors affecting the length of stay and hospital readmission rates after an acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Qing Wang; Guangsheng Pei; Lin Chen; Zhiyi He
Journal:  Ann Transl Med       Date:  2022-02

3.  Clinical Audit on Chronic Obstructive Pulmonary Disease (COPD) Management in Primary Care: A Quality Improvement Project from Hong Kong.

Authors:  Xiao Rui Catherine Chen; Sau Nga Fu; Wing Kit Leung; Sze Wing Catherine Ng; Wing Yan Wendy Kwan; Tseng Kwong Wong; Pang Fai Chan; Man Ying Michelle Wong; Wai Kit Welchie Ko; Jun Liang; Ming Tung Eric Hui; Yim Chu Li; Wan Luk; V K David Chao
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-06-23

4.  Correlates of disease-specific knowledge in Chinese patients with COPD.

Authors:  Carlos Kh Wong; W C Yu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-14

5.  Blood Eosinophil and Risk of Exacerbation in Chronic Obstructive Pulmonary Disease Patients: A Retrospective Cohort Analysis.

Authors:  Ming Chiu Chan; Yiu Cheong Yeung; Ellen Lok Man Yu; Wai Cho Yu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-11-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.